A share price of Marinus Pharmaceuticals Inc [MRNS] is currently trading at $1.66, up 3.75%. An important factor to consider is whether the stock is rising or falling in short-term value. The MRNS shares have gain 10.67% over the last week, with a monthly amount glided 21.17%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Marinus Pharmaceuticals Inc [NASDAQ: MRNS] stock has seen the most recent analyst activity on August 14, 2024, when Ladenburg Thalmann downgraded its rating to a Neutral. Previously, Robert W. Baird downgraded its rating to Neutral on April 16, 2024, and dropped its price target to $2. On April 15, 2024, downgrade downgraded it’s rating to Sector Perform and revised its price target to $3 on the stock. Oppenheimer downgraded its rating to a Perform and decreased its price target to $9 on August 11, 2023. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $23 as its price target on January 20, 2023. Truist started tracking with a Buy rating for this stock on September 30, 2020, and assigned it a price target of $35. In a note dated July 01, 2020, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $6 to $9.
Marinus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.05 and $11.26. Currently, Wall Street analysts expect the stock to reach $4.67 within the next 12 months. Marinus Pharmaceuticals Inc [NASDAQ: MRNS] shares were valued at $1.66 at the most recent close of the market. An investor can expect a potential return of 181.33% based on the average MRNS price forecast.
Analyzing the MRNS fundamentals
Trailing Twelve Months sales for Marinus Pharmaceuticals Inc [NASDAQ:MRNS] were 30.26M which represents 32.48% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -4.4%, Pretax Profit Margin comes in at -4.93%, and Net Profit Margin reading is -4.93%. To continue investigating profitability, this company’s Return on Assets is posted at -1.71, Equity is -79.35 and Total Capital is -2.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5800 points at the first support level, and at 1.5000 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7100, and for the 2nd resistance point, it is at 1.7600.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Marinus Pharmaceuticals Inc [NASDAQ:MRNS] is 2.28. On the other hand, the Quick Ratio is 2.15, and the Cash Ratio is 1.8. Considering the valuation of this stock, the price to sales ratio is 3.02.
Transactions by insiders
Recent insider trading involved Pfanstiel Steven, CFO AND COO, that happened on Aug 05 ’24 when 4657.0 shares were sold. CHIEF COMMERCIAL OFFICER, Shafer Christina completed a deal on Aug 05 ’24 to sell 3820.0 shares. Meanwhile, SVP, GEN. COUNSEL & CORP. SEC. MANNING MARTHA E sold 3621.0 shares on Aug 05 ’24.
